ATNM - Potential bottom reversal Largo

Actinium Pharmaceuticals, Inc. (Delaware)Arca

Descripción

⋅ 1 de Oct. de 2017 15:58

Insiders bought recently before the offering at $1.10 per share. Slightly risky when Actimab-A Phase 2 results could come out anytime.